CRISPR Therapeutics AG (CRSP)
| Market Cap | 3.59B |
| Revenue (ttm) | 170.10M |
| Net Income (ttm) | -415.93M |
| Shares Out | 79.41M |
| EPS (ttm) | -5.29 |
| PE Ratio | n/a |
| Forward PE | 23.36 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 64,829 |
| Open | 45.18 |
| Previous Close | 45.49 |
| Day's Range | 45.01 - 45.19 |
| 52-Week Range | 38.94 - 72.00 |
| Beta | 1.61 |
| Analysts | Buy |
| Price Target | 69.75 (+54.43%) |
| Earnings Date | Oct 31, 2023 |
About CRSP
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001,... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for CRSP stock is "Buy." The 12-month stock price forecast is $69.75, which is an increase of 54.43% from the latest price.
News
Are Gene Therapy Stocks The Market's Next Big Winners?
It's not often that you see a company whose main product comes with a price tag of over $2 million, but that's the case with biotechs BioMarin Pharmaceutical NASDAQ: BMRN and Sarepta Therapeutics NASD...
CRISPR Therapeutics Announces Leadership Transition
-CRISPR Therapeutics co-founder, Rodger Novak, M.D., to step down as President and Chairman, effective September 15, 2023- -Samarth Kulkarni, Ph.D., to succeed Dr. Novak as Chairman and will continue ...
CRISPR Therapeutics to Participate in Citi's 18th Annual Biopharma Conference
ZUG, Switzerland and BOSTON, Aug. 30, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious disea...
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
-FDA accepted Biologics License Applications (BLAs) for exagamglogene autotemcel (exa-cel) for severe Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT); Priority Review for SC...
3 Biotech Stocks to Buy for Long-Term Gains
Suppose you're looking for a sector that will benefit from an end to the Federal Reserve's interest rate hiking campaign. In that case, you may look at biotech stocks, a sector filled with long-dated ...
CRISPR Therapeutics to Participate in Goldman Sachs 44th Annual Global Healthcare Conference
ZUG, Switzerland and CAMBRIDGE, Mass., June 13, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ser...
Intellia Therapeutics stock gains on CRISPR treatment results
Intellia Therapeutics Inc. NTLA, -0.28% shares gained 6.4% premarket on Monday after the clinical stage genome-editing company announced new data from a trial of an investigational CRISPR-based therap...
Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress
BOSTON & ZUG, Switzerland--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced that both pivotal trials for exagamglogene autotem...
FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
BOSTON & ZUG, Switzerland--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced that the U.S. Food and Drug Administration (FDA) h...
Final Trades: Berkshire, Devon Energy & CRISPR Therapeutics
The "Halftime Report" traders give their top picks to watch for the second half.
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
-Regulatory submissions complete for exagamglogene autotemcel (exa-cel), formerly known as CTX001™, in the U.S. for transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD)-
CRISPR Therapeutics to Participate Upcoming Investor Conferences
ZUG, Switzerland and CAMBRIDGE, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for seri...
Crispr Therapeutics stock jumps following analyst upgrade from Cantor Fitzgerald
Yahoo Finance Live discusses a rise in Crispr Therapeutics stock after Cantor Fitzgerald upgraded the company to an 'Overweight' rating.
CRISPR Therapeutics to Participate in Needham's 22nd Annual Healthcare Conference
ZUG, Switzerland and CAMBRIDGE, Mass., April 13, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for se...
Cathie Wood Loads Up On Biotech Stocks — Continues To Raise Stake In Coinbase Global
Cathie Wood-led ARK Investment Management raised stakes in a number of biotech companies on Wednesday with these stocks recording negative returns over the last one month, potentially making them attr...
Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
BOSTON & ZUG, Switzerland--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced the completion of the rolling Biologics License Ap...
CRISPR Therapeutics Announces Departure of Board Member
ZUG, Switzerland and BOSTON, March 29, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious dise...
Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex's Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes
BOSTON & ZUG, Switzerland--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced that they have entered into a new non-exclusive li...
CRISPR Therapeutics to Present at the American Association for Cancer Research 2023 Annual Meeting
ZUG, Switzerland and BOSTON, March 14, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious dise...
CRISPR Therapeutics Announces Transition of Chief Financial Officer
ZUG, Switzerland and BOSTON, March 13, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious dise...
CRISPR Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference
ZUG, Switzerland and BOSTON, Feb. 27, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious disea...
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
-Regulatory submissions complete for exagamglogene autotemcel (exa-cel) in Europe for transfusion-dependent beta thalassemia (TDT) and sickle cell disease (SCD); U.S. rolling Biologics Licensing Appli...
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
ZUG, Switzerland and CAMBRIDGE, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ser...